Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors

This is a single-arm, open-label phase 2 study to evaluate the role of pacritinib for patients with metastatic castrate-resistant prostate cancer that have progressed on ARSI. Patients will receive pacritinib 200 mg twice daily. To be eligible, patients must have a biopsy of a metastatic site within 30 days of treatment that demonstrates positive STAT5 activation status

NCT Number	NCT07226713
Lead Sponsor	Medical College of Wisconsin
Conditions	Prostate Cancer
Enrollment	32 participants
Start Date	2026-07-01
Primary Completion	2029-03-01 (estimated)
Study Completion	2031-03-01 (estimated)
Updated on ClinicalTrials.gov	2026-05-04